Arca
Skip to content
Tools
Tools

GFRA1: GDNF family receptor alpha-1

Coreceptor for GDNF, a neurotrophic factor that enhances survival and morphological differentiation of dopaminergic neurons and increases their high-affinity dopamine uptake.

  • Drugs that act on it: 1
  • Approved: 0
  • In phases 1 to 3: 1
  • Sponsors: 1

Who is on it, and how far along

Every drug ChEMBL records acting on GFRA1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Protein or peptide 1

Approved0

    Phase 30

      Phase 21

      • Liatermin

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        DrugFurthest stageSponsorModalityActionOpen trials
        LiaterminPhase 2Brain Neurotherapy Bio, Inc.Protein or peptideAgonistGDNF family receptor alpha-1 agonist3

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 3 in all, from ClinicalTrials.gov.
        CNS10-NPC-GDNF Delivered to the Motor Cortex for ALSLiaterminPhase 1Active, not recruitingCedars-Sinai Medical CenterApr 1, 2022
        GDNF Gene Therapy for Multiple System AtrophyLiaterminPhase 1Active, not recruitingBrain Neurotherapy Bio, Inc.Dec 22, 2020
        GDNF Gene Therapy for Parkinson's DiseaseLiaterminPhase 1Active, not recruitingBrain Neurotherapy Bio, Inc.Nov 19, 2019

        Diseases most associated with it

        Open Targets association score, 0 to 1; all associations
        • Renal hypodysplasia/aplasia 40.47
        • Renal agenesis0.38
        • Bilateral renal agenesis0.37
        • Smoking initiation0.36
        • Bone Paget disease0.31
        • Hirschsprung disease0.26
        • Contracture0.24
        • Bile duct disorder0.24
        • Stroke disorder0.23
        • Neurodegenerative disease0.19

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3833481, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P56159, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.